In last trading session, Kyverna Therapeutics Inc (NASDAQ:KYTX) saw 0.34 million shares changing hands with its beta currently measuring 2.97. Company’s recent per share price level of $2.78 trading at -$0.06 or -2.11% at ring of the bell on the day assigns it a market valuation of $120.02M. That closing price of KYTX’s stock is at a discount of -1000.72% from its 52-week high price of $30.60 and is indicating a premium of 5.04% from its 52-week low price of $2.64.
For Kyverna Therapeutics Inc (KYTX), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.29. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 0 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.79 in the current quarter.
Kyverna Therapeutics Inc (NASDAQ:KYTX) trade information
Upright in the red during last session for losing -2.11%, in the last five days KYTX remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $2.78 price level, adding 14.2% to its value on the day. Kyverna Therapeutics Inc’s shares saw a change of -25.67% in year-to-date performance and have moved -8.55% in past 5-day. Kyverna Therapeutics Inc (NASDAQ:KYTX) showed a performance of -15.50% in past 30-days.
Kyverna Therapeutics Inc (KYTX) estimates and forecasts
In 2025, company’s earnings growth rate is likely to be around 96.32% while estimates for its earnings growth in next 5 years are of 66.11%.
On the other hand, JP Morgan Small Cap Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.03 shares of worth $2.87 million or 2.39% of the total outstanding shares. The later fund manager was in possession of 633.84 shares on Sep 30, 2024 , making its stake of worth around $1.76 million in the company or a holder of 1.47% of company’s stock.
